тел. +38 (044) 483-12-82

№4(6) 2023

Укр

DOI 10.37219/2528-8253-2023-4-39

Mousa A, Dieeva JV

CHRONIC RHINOSINUSITIS – DIAGNOSTIC VALUE OF ENDOTYPES

Mousa Ahmad
Bogomolets National Medical University, Kyiv, Ukraine
Postgraduate student in the Department of Otorhinolaryngology
E-mail: alsabbar@hotmail.com
ORCID ID: https://orcid.org/0000-0003-1932-2256

Dieieva Julia V.
Bogomolets National Medical University, Kyiv, Ukraine
Head of the department of Otorhinolaryngology
MD, PhD, professor
E-mail: deyeva@bigmir.net
ORCID ID: https://orcid.org/0000-0003-0552-1254
https://www.scopus.com/authid/detail.uri?authorId=55359076200

Abstract

Topicality: The study of the quality of life of patients with ENT pathology along with a complex clinical and functional study makes it possible to make a complete and objective picture of the quality of treatment of the disease. The impact of both the disease itself and pharmacological treatment on the physical and psychoemotional state initiates the emergence of a number of problems with social adaptation and self-assessment of the quality of life in society, as well as the quality of the assessment of treatment results.

Objective: study of the effect of the side effect of systemic antibacterial therapy in the form of dysbiosis of the gastrointestinal tract in the treatment of patients with exacerbation of chronic rhinosinusitis without polyps on the assessment of quality of life before and after treatment.

Results: If we compare the average total score before and after treatment, we will see that on the 10th day of therapy, according to the questionnaire, her results are probably better (at Р<0.05) in the group where she was treated with a synbiotic, and in the group with treatment without synbiotics, there is a difference, but it is not significant (at P>0.05). Limitation of life activity and the degree of deterioration of well-being due to specific otorhinolaryngological criteria (the first 12 points of the SNOT-22 questionnaire) in patients with exacerbation of chronic rhinosinusitis without polyps when treated both with and without synbiotics are likely to decrease on the 10th day of therapy. Analyzing the constituent scales of the psychological component of health, we observe the deterioration of the physical and emotional state, the limitation of social activity before treatment and after treatment without the use of synbiotics. Depressive and hypochondriacal syndromes prevailed in patients of the control group, accordingly, the general state of health remained poor, decreased vital activity due to almost all criteria, starting from the 13th to the 22nd. However, specific otorhinolaryngological criteria of symptoms of exacerbation of chronic rhinosinusitis without polyps in the control group were likely to improve after treatment.

Conclusions: The evaluation of the severity of the course of exacerbation of chronic rhinosinusitis without polyps and the quality of treatment of patients with the use of systemic antibiotic therapy, when using the SNOT-22 questionnaire, is influenced by such a factor of comorbidity as dysbiosis of the gastrointestinal tract. The use of a synbiotic in a dose of 2 capsules once a day during meals for 10 days from the first day of taking the antibiotic in a complex of therapeutic measures in patients with an exacerbation of chronic rhinosinusitis without polyps improves the quality of life of patients and improves the assessment of the effectiveness of treatment in dynamics.

Keywords: chronic rhinosinusitis, comorbid condition, quality of life questionnaire, antibiotic therapy, synbiotic.

Download.PDF

References

  1. de Loos DD, Lourijsen ES, Wildeman MAM, Freling NJM, Wolvers MDJ, Reitsma S, Fokkens Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol. 2019 Mar;143(3):1207-1214. doi: 10.1016/j.jaci.2018.12.986.
  2. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S,  et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
  3. Bachert C, Pawankar R, Zhang L, Bunnag C, Fokkens WJ,  et al. ICON: chronic rhinosinusitis. World Allergy Organ J. 2014 Oct 27;7(1):25. doi: 10.1186/1939-4551-7-25.
  4. Orlandi RR, Marple BF. The role of fungus in chronic rhinosinusitis. Otolaryngol Clin North Am. 2010 Jun;43(3):531-7, viii. doi: 10.1016/j.otc.2010.02.011.
  5. Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013 Jun;131(6):1479-90. doi: 10.1016/j.jaci.2013.02.036.
  6. Wei B, Liu F, Zhang J, Liu Y,Du J, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population. Rhinology. 2018 Sep 1;56(3):216-226. doi: 10.4193/Rhin17.240.
  7. Tomassen P, Vandeplas G, Van Zele T, Cardell L-O, ArebroJ,  et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016; 137(5): 1449-1456.e4. doi: 10.1016/j.jaci.2015.12.1324. 
  8. Jarvis D, Newson R, Lotvall J, Hastan D,Tomassen P, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012 Jan;67(1):91-8. doi: 10.1111/j.1398-9995.2011.02709.x.
  9. Hakansson K, Thomsen SF, Konge L, Mortensen J, Backer V, von Buchwald C. A comparative and descriptive study of asthma in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014 Sep-Oct;28(5):383-7. doi: 10.2500/ajra.2014.28.4076.
  10. Samitas K, Carter A, Kariyawasam HH, Xanthou G. Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: The one airway concept revisited. Allergy. 2018 May;73(5):993-1002. doi: 10.1111/all.13373.
  11. Hirotsu M, Kikuchi K, Kusunoki T, Kase K, Ono N, Ikeda K. Comparison of bacterial examinations between eosinophilic and neutrophilic chronic rhinosinusitis with nasal polyps. Acta Otolaryngol. 2011 Sep;131(9):997-1001. doi: 10.3109/00016489.2011.576430.
  12. Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, et al. Subclassification of chronic rhinosinusitis with nasal polyp based on eosinophil and neutrophil. Laryngoscope. 2013 Nov;123 (11):E1-9. doi: 10.1002/lary.24154.
  13. Lin H, Lin D, Xiong XS, Dai XX, Lin T. Role of platelet-derived growth factor-α in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2014 Nov;4(11):909-14. doi: 10.1002/alr.21419.
  14. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, SagelSD, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol. 2016 Feb;51 (2):115-32. doi: 10.1002/ppul.23304.
  15. Wood AJ, Antoszewska H, Fraser J, Douglas RG. Is chronic rhinosinusitis caused by persistent respiratory virus infection? Int Forum Allergy Rhinol. 2011;1(2):95-100. doi: 10.1002/alr.20030.
  16. Vickery TW, Ramakrishnan VR, Suh The Role of Staphylococcus aureus in Patients with Chronic Sinusitis and Nasal Polyposis. Curr Allergy Asthma Rep. 2019 Mar 11;19(4):21. doi: 10.1007/s11882-019-0853-7.
  17. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, Lin P, Bousquet J, Van Steen K. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010 Nov;126(5):962-8, 968.e1-6. doi: 10.1016/j.jaci.2010.07.007.
  18. Cheng K-J, Wang S-Q, Xu Y-Y. Different roles of Staphylococcus aureus enterotoxin in different subtypes of nasal polyps. Exp Ther Med. 2017 Jan; 13(1):321-326. doi: 10.3892/etm.2016.3951.
  19. Semic-Jusufagic A, Bachert C, Gevaert P, Holtappels G, Lowe L, Woodcock A, Simpson A, Custovic A. Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study. J Allergy Clin Immunol. 2007 Apr;119(4):930-6. doi: 10.1016/j.jaci.2006.12.639.
  20. Jandus P, Harr T, Soyka MB, Landis BN. The efficacy of omalizumab in the treatment of chronic rhinosinusitis with nasal polyps: a discussion of 2 refractory cases. Rev Med Suisse. 2019 Oct 2;15(665):1748-1751. [Article in French].
  21. Rihet P,  Demeure CE,Bourgois A,Prata A,  Dessein Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur J Immunol. 1991 Nov; 21(11):2679-86. doi: 10.1002/eji.1830211106.
  22. Pritchard DI,  Quinnell RJ, Walsh Immunity in humans to Necator americanus: IgE, parasite weight and fecundity. Parasite Immunol. 1995 Feb;17(2):71-5. doi: 10.1111/j.1365-3024.1995.tb00968.x.
  23. Permin H,Wiik The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus. Acta Pathol Microbiol Scand C. 1978 Oct;86C(5):245-9. doi: 10.1111/j.1699-0463.1978.tb02587.x.
  24. Elkayam O, Tamir R, Pick AI,Wysenbeek Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus. Allergy. 1995 Jan;50(1):94-6.
  25. Karagiannis SN, Wang Q,East N,Burke F, Riffard S,  Bracher MG, et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40. doi: 10.1002/ 200323185.